Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paliz is a brand of pharmaceutical products containing pantoprazole, developed and marketed by LIA LIFE SCIENCES. Pantoprazole is a proton pump inhibitor (PPI) that irreversibly binds to the H+/K+ ATPase enzyme system (the proton pump) in gastric parietal cells, thereby inhibiting the final step of gastric acid secretion. It is used for the treatment of acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD), dyspepsia, and gastritis. The Paliz product line includes oral tablets (Paliz 40mg), combination products with the anti-dopaminergic prokinetic agent domperidone (Paliz-D), and intravenous formulations (Paliz IV). These products are approved and marketed in India.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Paliz.